ProPharma Group, a portfolio company of Odyssey Investment Partners, announces the acquisition of Diamond Pharma Services, a provider of regulatory affairs, pharmacovigilance, and compliance & quality services that support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licenses throughout all stages of a product’s life cycle.
With global presence and headquarters based in Harlow, United Kingdom, Diamond Pharma brings a suite of regulatory, pharmacovigilance, and compliance and quality services to ProPharma. Diamond’s team will aim to accelerate the value ProPharma Group brings in delivering regulatory science to companies working on therapeutics with ProPharma Group’s ATMPs/Cell and Gene Therapy Center of Excellence.
“We are excited to welcome Diamond Pharma Services into the ProPharma Group family,” said Dawn Sherman, ProPharma Group, CEO. “This acquisition further solidifies ProPharma Group’s position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services. With our mission and higher purpose of improving the health and safety of patients, we are focused on delivering the highest quality of services throughout the full product lifecycle.”
Achelous Partners served as M&A advisor to Diamond Pharma Services on the transaction.